Coagulopathy in COVID-19: Focus on vascular thrombotic events.
J Mol Cell Cardiol
; 146: 32-40, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-650924
ABSTRACT
SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows COVID-19 conferring enormous challenge for clinicians worldwide, and developing to a pandemic level. Combined with a series of complications, a part of COVID-19 patients progress into severe cases, which critically contributes to the risk of fatality. To date, coagulopathy has been found as a prominent feature of COVID-19 and severe coagulation dysfunction may be associated with poor prognosis. Coagulopathy in COVID-19 may predispose patients to hypercoagulability-related disorders including thrombosis and even fatal vascular events. Inflammatory storm, uncontrolled inflammation-mediated endothelial injury and renin angiotensin system (RAS) dysregulation are the potential mechanisms. Ongoing efforts made to develop promising therapies provide several potential strategies for hypercoagulability in COVID-19. In this review, we introduce the clinical features of coagulation and the increased vascular thrombotic risk conferred by coagulopathy according to present reports about COVID-19. The potential underlying mechanisms and emerging therapeutic avenues are discussed, emphasizing an urgent need for effective interventions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Pulmonary Embolism
/
Respiratory Insufficiency
/
Coronavirus Infections
/
Disseminated Intravascular Coagulation
/
Betacoronavirus
/
Cytokine Release Syndrome
/
Anticoagulants
Type of study:
Prognostic study
Topics:
Long Covid
Language:
English
Journal:
J Mol Cell Cardiol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS